Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States

References

• Adult Acute Lymphoblastic Leukemia Treatment (PDQ(R)): Health Professional Version. PDQ Adult Treatment Editorial Board. In: PDQ cancer information summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002; 2018 Mar 22.
   Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: acute lymphoblastic leukemia. Version 5. 2017 [cited 2018 Jan 29]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf
   Google Scholar
• Bassan R, Gatta G, Tondini C, et al. Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol. 2004;50(3):223–261.
   PubMed Web of Science ®Google Scholar
• Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al., editors. SEER cancer statistics review, 1975-2014: leukemia, acute lymphocytic leukemia. Age-adjusted SEER incidence. National Cancer Institute; 2017 [cited 2018 Jan 29]. Available from: https://seer.cancer.gov/csr/1975_2014/results_merged/sect_13_leukemia.pdf
   Google Scholar
• American Cancer Society. About Acute Lymphocytic Leukemia (ALL): key statistics for acute lymphocytic leukemia. 2018 [cited 2018 Jan 29]. Available from: https://www.cancer.org/cancer/acute-lymphocytic-leukemia/about/key-statistics.html
   Google Scholar
• Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532–543.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines for patients: acute lymphoblastic leukemia. Version 1. 2017 [cited 2018 Jun 5]. Available from: https://www.nccn.org/patients/guidelines/all/index.html#30/z
   Google Scholar
• Mei L, Ontiveros EP, Griffiths EA, et al. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev. 2015;29(4):243–249.
   PubMed Web of Science ®Google Scholar
• Brown PA, Shah B, Fathi A, et al. NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2017. J Natl Compr Canc Netw. 2017;15(9):1091–1102.
   PubMed Web of Science ®Google Scholar
• Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood. 2013;121(7):1077–1082.
   PubMed Web of Science ®Google Scholar
• Lamanna N, von Hassel M, Weiss M. Relapsed acute lymphoblastic leukemia. In: Acute leukemias. Hematologic Malignancies. Springer, Berlin, Heidelberg; 2008. p. 275–279.
   Google Scholar
• Oriol A, Vives S, Hernández-Rivas J-M, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group. Haematologica. 2010;95(4):589–596.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944–950.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010;116(24):5568–5574.
   PubMed Web of Science ®Google Scholar
• Pui C-H, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov. 2007;6(2):149–165.
   PubMed Web of Science ®Google Scholar
• Hummel HDT, Chang MS, Chia ET, et al. Events in adults with relapsed or refractory Acute Lymphoblastic Leukemia (ALL): a literature review of recent clinical trials. J Leuk. 2016;4(1):208.
   Google Scholar
• Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Malerba L, et al. Infectious complications in adult acute lymphoblastic leukemia (ALL): experience at one single center. Leuk Lymphoma. 2004;45(8):1617–1621.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847.
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Muller K, Mogensen SS, et al. Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Res. 2017;6:444.
   PubMedGoogle Scholar
• The Leukemia & Lymphoma Society. Chimeric Antigen Receptor (CAR) T-cell therapy. 2018 [cited 2018 Jan 29]. Available from: http://www.lls.org/treatment/types-of-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy
   Google Scholar
• Daver N, O’Brien S. Novel therapeutic strategies in adult acute lymphoblastic leukemia – a focus on emerging monoclonal antibodies. Curr Hematol Malig Rep. 2013;8(2):123–131.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032–2041.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–753.
   PubMed Web of Science ®Google Scholar
• Barlev A, Lin VW, Song X. Burden of hospitalization in relapsed acute lymphoblastic leukemia. Curr Med Res Opin. 2016;32(7):1209–1212.
   PubMed Web of Science ®Google Scholar
• Bhowmik D, Song X, Intorcia M, et al. Healthcare resource use and costs associated with chronic kidney disease in US private insurance patients with multiple myeloma. J Oncol Pharm Pract. 2018;1078155218766408. [Epub ahead of print]
   Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448.
   PubMed Web of Science ®Google Scholar
• Bryant AL, Deal AM, Walton A, et al. Use of ED and hospital services for patients with acute leukemia after induction therapy: one year follow-up. Leuk Res. 2015;39(4):406–410.
   PubMed Web of Science ®Google Scholar
• Garcia JB, Lei X, Wierda W, et al. Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thorac Soc. 2013;10(5):432–440.
   PubMedGoogle Scholar
• Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2014;6(1):e2014073.
   PubMedGoogle Scholar
• Leukemia and Lymphoma Society. Ph Positive ALL Therapy. 2018 [cited 2018 Jun 5]. Available from: https://www.lls.org/leukemia/acute-lymphoblastic-leukemia/treatment/ph-positive-all-therapy
   Google Scholar